It has been reported that oncogenic KRAS mutations, and subsequent activation of the downstream effectors, such as Erk, Akt, and MEK, can result in the modulation of pancreatic cancer (Kamerkar et al., 2017). Here, MAPK1 is linked to pancreatic neoplasm.